Clinical trials: Vascular Conditions
Coronary Artery Disease, Arterial Occlusive Diseases
The ENDEAVOR II Clinical Trial: The Medtronic Endeavor Drug Eluting Coronary Stent System in Coronary Artery Lesions
To demonstrate the safety and efficacy of the Driver Coronary Stent coated with 10 mcg/mm ABT-578 compared to the uncoated Driver Stent for the treatment of single de novo lesions in native coronary arteries 2.25-3.5 mm in…
- Conditions
- Coronary Artery Disease, Arterial Occlusive Diseases, Coronary Disease, Coronary Arteriosclerosis
- Trial name
- ENDEAVOR II (NCT00614848)
- Testing
- Endeavor drug eluting coronary stent
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- Medtronic Vascular
Diabetic Foot Ulcer
Nitric Oxide Generating Gel Dressing in Patients With Diabetic Foot Ulcers
This is a 2 part study to assess the safety and efficacy of a nitric oxide (NOx) generating dressing on chronic diabetic foot ulcers (DFU). Nitric oxide has a range of effects on the body including vasodilation and angiogenesis.
- Trial name
- ProNOx1 (NCT01982565)
- Testing
- NOx dressing, Standard of Care
- Where
- 10 sites in United Kingdom
- Volunteers
- 130 people
- Sponsor
- Edixomed Ltd
Diabetic Retinopathy, Posterior Vitreous Detachment
A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR
The purpose of this study is to assess the efficacy and safety of up to 3 intravitreal injections of ocriplasmin (0.0625mg or 0.125mg), in subjects with moderate to very severe non-proliferative diabetic retinopathy (NPDR), to…
- Conditions
- Diabetic Retinopathy, Posterior Vitreous Detachment, Disease Progression
- Trial name
- CIRCLE (NCT02681809)
- Testing
- ocriplasmin 0.0625mg, ocriplasmin 0.125mg
- Where
- 38 sites in United States, Czechia and 7 more
- Volunteers
- 48 people
- Sponsor
- ThromboGenics
Carotid Stenosis, Atherosclerosis
Revacept in Symptomatic Carotid Stenosis
Patients suffering from symptomatic carotid artery stenosis, transient ischemic attacks (TIAs), amaurosis fugax or stroke receive either Revacept (single dose) plus antiplatelet monotherapy or monotherapy alone.
- Conditions
- Carotid Stenosis, Atherosclerosis, Stroke, Transient-ischaemic Attack
- Trial name
- RevaceptCS02 (NCT01645306)
- Testing
- Revacept
- Where
- 12 sites in Germany, United Kingdom
- Volunteers
- 158 people
- Sponsor
- AdvanceCor GmbH
End-Stage Kidney Disease (ESKD)
Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis
This study will evaluate three Investigational Medicinal Products (IMPs) called REGN9933, REGN7508, and REGN9533. The study is focused on participants with End-Stage Kidney Disease (ESKD) treated with hemodialysis and standard…
- Trial name
- NCT07759167
- Testing
- REGN9933, REGN7508, REGN9533
- Where
- Belgium
- Volunteers
- 36 people
- Sponsor
- Regeneron Pharmaceuticals
Relapsed or Refractory Multiple Myeloma
Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet
A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone
- Trial name
- SELECT (NCT04191616)
- Testing
- Carfilzomib, Dexamethasone, Pomalidomide
- Where
- 46 sites in United States, Denmark and 6 more
- Volunteers
- 54 people
- Sponsor
- Amgen
Venous Ulcer, Pressure Ulcer
Safety and Efficacy of the Fruit-based Product OPAL A for the Treatment of Chronic Venous and Pressure Ulcers
The purpose of this study is to examine the safety and efficacy of the fruit-based product OPAL A for the treatment of chronic venous and pressure ulcers.
- Trial name
- NCT00933348
- Testing
- OPAL A
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- Phoenix Eagle Company
Rosacea, Vascular Diseases
Vbeam Pro Pulse Dye Laser for the Treatment of Vascular Conditions
This is a clinical study to evaluate the safety and performance of the Vbeam Pro Laser System for the treatment of vascular indications, including rosacea and port wine stain birthmarks.
- Conditions
- Rosacea, Vascular Diseases, Port-Wine Stain
- Trial name
- NCT07290426
- Testing
- Vbeam Pro Laser Treatment
- Where
- Spain
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Candela Corporation
Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
This study is for patients with lymphoproliferative malignancies that have progressed after receiving a previous treatment (relapsed) or are no longer responding to treatment (refractory).
- Conditions
- Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma, B-cell Lymphoma
- Trial name
- NCT00481871
- Testing
- Pralatrexate Injection, Gemcitabine Hydrochloride, Vitamin B12
- Where
- 15 sites in United States
- Volunteers
- 119 people
- Sponsor
- Acrotech Biopharma Inc.
ST-segment Elevation Myocardial Infarction
Phase 2 Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients
Evaluate the efficacy, Safety and Pharmacokinetics of Intravenous single injection LC28-0126 immediately before PCI (Percutaneous Coronary Intervention) in Patients with STEMI (ST-segment Elevation Myocardial Infarction)
- Trial name
- NCT02070471
- Testing
- LC28-0126 Dose A, LC28-0126 Dose B, LC28-0126 Dose C
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- LG Life Sciences
Chronic Stable Angina
Capadenoson in Angina Pectoris
This is a multi-center and multi-national,randomized, double blind, placebo-controlled, 28-day treatment study with BAY 68-4986 taken orally or a matching placebo.
- Trial name
- NCT00518921
- Testing
- Capadenoson (BAY 68-4986)
- Where
- 36 sites in Czechia, Hungary and 4 more
- Sponsor
- Bayer
Venous Ulcer, Venous Stasis Ulcer
Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers
This study is being done to find out if an investigational product called HP802-247 can help people with venous leg ulcers. Investigational means that HP802-247 has not been approved by the U.S.
- Conditions
- Venous Ulcer, Venous Stasis Ulcer, Ulcer
- Trial name
- NCT01853384
- Testing
- HP802-247, HP802-247 Vehicle
- Where
- 46 sites in Belgium, Czechia and 3 more
- Volunteers
- 252 people
- Sponsor
- Healthpoint
Myocardial Infarction
AngioJET Thrombectomy and STENTing for Treatment of Acute Myocardial Infarction
The purpose of this study is to determine whether prompt removal of thrombus (blood clot) from a blocked coronary artery using the AngioJet rheolytic thrombectomy device will result in improved blood flow within the heart and a…
- Trial name
- NCT00275990
- Testing
- rheolytic thrombectomy with direct stenting, direct stenting
- Where
- Italy
- Volunteers
- 501 people
- Sponsor
- Boston Scientific Corporation
Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults
This study is a randomized, double-blind, sponsor-open, placebo-controlled study. It will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered single and multiple doses of EDP-978 in…
- Trial name
- NCT07540910
- Testing
- EDP-978
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Silent Myocardial Infarction, Stable Angina
Comparative Phase IV Study: Efficacy And Safety of TiTAN2 Versus COBALT-CHROME Stents- EVIDENCEII
The purpose of this study is to compare the effectiveness and safety, at 24 months, of the TITAN2 stent to any bare-metal stent (BMS) in Cobalt-Chromium in a population presenting an indication for these stents among 40% of which…
- Conditions
- Silent Myocardial Infarction, Stable Angina, Acute Coronary Syndrome
- Trial name
- EVIDENCE II (NCT01918150)
- Testing
- Titan 2 stents, Cobalt-Chromium Bare Metal Stents
- Where
- 42 sites in France
- Volunteers
- 1,350 people
- Sponsor
- Hexacath, France
Chronic Cerebral Ischemia
Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia
The purpose of this study is to evaluate safety and efficacy of sequential treatment with Mexidol® in patients with chronic cerebral ischemia (CCI).
- Trial name
- MEMO (NCT06834490)
- Testing
- Mexidol
- Where
- 14 sites in Russia, Uzbekistan
- Volunteers
- 318 people
- Sponsor
- Pharmasoft
Hematological Malignancies
Study of IV CBL0137 in Previously Treated Hematological Subjects
This clinical trial is a Phase 1, open-label, sequential-group, dose-escalation (Part 1) and cohort-expansion study (Part 2) evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of intravenously (IV)…
- Trial name
- NCT02931110
- Testing
- CBL0137
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Incuron
Peripheral Vascular Disease
Trial to Evaluate the Safety & Efficacy of the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery
To determine the safety and efficacy of the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in subjects with atherosclerotic de novo or restenotic lesions in the native common iliac artery and/or native external iliac…
- Trial name
- MOBILITY OE (NCT01396525)
- Testing
- Omnilink Elite™ Peripheral Balloon-Expandable Stent System
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- Abbott Medical Devices
Chronic Spontaneous Urticaria
A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients
A safety extension study to evaluate the long-term safety of QGE031 240 mg s.c. given every 4 weeks for 52 weeks in Chronic Spontaneous Urticaria (CSU) patients who completed study CQGE031C2201
- Trial name
- NCT02649218
- Testing
- Ligelizumab
- Where
- 67 sites in United States, Australia and 8 more
- Volunteers
- 226 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Stenosis
EluNIR Ridaforolimus Eluting Coronary Stent System in Patients at High Bleeding Risk (HBR)- EluNIR HBR Study
The study will enroll approximately 316 subjects with a wide spectrum of PCI indications (stable angina as well as ACS), who are considered to be at high risk of bleeding.
- Trial name
- NCT03877848
- Testing
- Percutaneous Coronary Intervention (PCI)
- Where
- Israel
- Volunteers
- 319 people
- Sponsor
- Medinol Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.